Event Brief
May 18, 2026 at 8:02 AM ET
Daraxonrasib pill shows promise in early pancreatic cancer trial
By The BriefBrief
Daraxonrasib, a daily pill targeting RAS-linked signals, completed a first-in-human trial in 168 patients with advanced pancreatic cancer.
WHO: Dana-Farber Cancer Institute
WHAT: First-in-human trial of daraxonrasib in 168 patients with advanced pancreatic cancer and RAS mutations evaluated safety and effectiveness.
WHEN: May 18, 2026 at 7:00 AM ET
WHERE: Location not specified
WHY: The drug was tested to evaluate its safety and effectiveness in people with advanced pancreatic cancer with RAS mutations.
Reporting from 1 identified publisher for this event.
View all 1 publishers
Publishers represented across this event arc
These publishers contributed reporting to the broader event history. Not every source addresses the specific development described above.
How this brief is built: The BriefBrief correlates multiple sources into one evolving event brief, updated as new facts emerge.
Senior presidential advisor dies in car accident
Moses Karangwa Kalisa
May 18, 2026 at 8:05 AM ET
Iran says nuclear enrichment rights cannot be negotiated
Middle-East
May 18, 2026 at 8:05 AM ET
Trial begins for WA police assistant commissioner stalking
World
May 18, 2026 at 8:05 AM ET
Tyler Robinson seeks more secret hearings after camera loss
Us
May 18, 2026 at 8:02 AM ET
Page 18261 of 21450
Same format. Every time.
Continue reading — sign in or create a free account with
